Loading...
•
Sep 30, 2022
Maravai Q3 2022 Earnings Report
Reported solid results driven by Nucleic Acid Production and Biologics Safety Testing revenues, while also updating revenue, Adjusted EBITDA, and Adjusted EPS guidance for 2022.
Key Takeaways
Maravai LifeSciences reported a revenue of $191.3 million for Q3 2022, with a net income of $99.7 million and Adjusted EBITDA margins of 69%. The revenue includes $16.4 million from Biologics Safety Testing, $48.4 million from Nucleic Acid Production base business, and $126.5 million from COVID-19 related CleanCap® revenue.
Total revenues reached $191.3 million.
Net income was $99.7 million.
Adjusted EBITDA margins were 69%.
Expanded mRNA raw material offering with GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate.
Revenue by Segment
Forward Guidance
Total revenue for 2022 is projected to be in the range of $880.0 million to $890.0 million, reflecting overall year-over-year growth of 10% to 11%. Adjusted EBITDA (non-GAAP) is now expected to be in the range of $650.0 million to $660.0 million. Adjusted fully diluted EPS (non-GAAP) is now expected to be in the range of $1.76 - $1.80 per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...